HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bertram, L. Articles by Tanzi, R. E Search for Related Content PubMed PubMed Citation Articles by Bertram, L. Articles by Tanzi, R. E Pubmed/NCBI databases Gene GEO Profiles HomoloGene Nucleotide Protein UniGene Substance via MeSH Medline Plus Health Information Alzheimer's Disease

Is -T catenin (VR22) an Alzheimer’s disease risk gene?

¹ Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Diseases, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Massachusetts, USA
² Gerontology Research Unit, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Massachusetts, USA
³ TorreyPines Therapeutics, La Jolla, California, USA

Correspondence to:
Dr L Bertram
Genetics and Aging Research Unit, Massachusetts General Hospital-East (MassGeneral Institute for Neurodegenerative Diseases), 114, 16th Street, Charlestown, MA 02129, USA; bertram{at}helix.mgh.harvard.edu] Background: Recently, conflicting reports have been published on the potential role of genetic variants in the -T catenin gene (VR22; CTNNA3) on the risk for Alzheimer’s disease. In these papers, evidence for association is mostly observed in multiplex families with Alzheimer’s disease, whereas case–control samples of sporadic Alzheimer’s disease are predominantly negative.

Methods: After sequencing VR22 in multiplex families with Alzheimer’s disease linked to chromosome 10q21, we identified a novel non-synonymous (Ser596Asn; rs4548513) single nucleotide polymorphism (SNP). This and four non-coding SNPs were assessed in two independent samples of families with Alzheimer’s disease, one with 1439 subjects from 437 multiplex families with Alzheimer’s disease and the other with 489 subjects from 217 discordant sibships.

Results: A weak association with the Ser596Asn SNP in the multiplex sample, predominantly in families with late-onset Alzheimer’s disease (p = 0.02), was observed. However, this association does not seem to contribute substantially to the chromosome 10 Alzheimer’s disease linkage signal that we and others have reported previously. No evidence was found of association with any of the four additional SNPs tested in the multiplex families with Alzheimer’s disease. Finally, the Ser596Asn change was not associated with the risk for Alzheimer’s disease in the independent discordant sibship sample.

Conclusions: This is the first study to report evidence of an association between a potentially functional, non-synonymous SNP in VR22 and the risk for Alzheimer’s disease. As the underlying effects are probably small, and are only seen in families with multiple affected members, the population-wide significance of this finding remains to be determined.

Abbreviations: CAG, Consortium on Alzheimer’s Genetics; NIMH, National Institute of Mental Health; SNP, single-nucleotide polymorphism

This article has been cited by other articles:

				A. Miyashita, H. Arai, T. Asada, M. Imagawa, E. Matsubara, M. Shoji, S. Higuchi, K. Urakami, A. Kakita, H. Takahashi, et al. Genetic association of CTNNA3 with late-onset Alzheimer's disease in females Hum. Mol. Genet., December 1, 2007; 16(23): 2854 - 2869. [Abstract] [Full Text] [PDF]